MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference
September 26 2019 - 9:00AM
MannKind Corporation (NASDAQ: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension, announced today that it will
be featured as a presenting company at the 2019 Cantor Global
Healthcare Conference on Thursday, October 3, 2019 at 9:30 am (ET)
at the InterContinental New York Barclay Hotel in New York City.
Presenting from the Company will be its Chief Executive Officer,
Michael Castagna.
The presentation will be webcast live.
Interested parties can access a link to the live webcast of the
presentation from the News & Events section of the Company's
website at http://www.mannkindcorp.com. The webcast replay will
remain available for 14 days following the live presentation.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only orally
inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company Contact:Rose
AlinayaInvestor Relations818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024